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Feline rhinotracheitis is a ubiquitous disease caused by feline herpesvirus type 1 (FHV-1). 
The disease is easily transmissible and common in multi-cat environments where even 
vaccinated cats can develop clinical signs of respiratory or ocular disease or both when 
exposed to the virus. Prior to the work reported here, there was no licensed treatment 
for the disease on the market. We hypothesized that polyprenyl immunostimulant (PI), an 
immunomodulatory veterinary biologic, would be useful in treating feline rhinotracheitis by 
reducing the severity of respiratory or/and ocular disease. We conducted double-blinded, 
randomized, placebo-controlled clinical trials in experimentally infected cats to establish 
the efficacy of PI. Specific pathogen-free cats were administered a placebo (n = 20) or PI 
(n = 20) starting on the day of FHV-1 experimental challenge. Trained, masked observers 
applied a standardized scoring system daily in clinical examinations for 14 days after the 
FHV-1 challenge. The cats treated with PI had significantly lower disease severity scores 
over the course of the experiment compared to the cats in the placebo group (p = 0.05). 
The safety studies, including a field safety study involving 390 owned cats in 10 states, 
showed that PI was safe to use in cats as young as 8 weeks of age.
Keywords: feline rhinotracheitis, polyprenyl immunostimulant, feline herpesvirus, upper respiratory tract disease, 
clinical trials, treatment, clinical efficacy
inTrODUcTiOn
Upper respiratory tract disease (URTD) is a common illness in cats that occurs worldwide. The 
principal agents of URTDs in domestic cats are feline herpesvirus type 1 (FHV-1) that causes 
rhinotracheitis and feline calicivirus (1). FHV-1 is highly contagious and easily spread between 
susceptible cats. URTD is a major cause of morbidity in multi-cat households such as breeding 
colonies, boarding catteries and shelters, and exposure of naïve cats to those environments leads to 
a high incidence of the disease (1, 2). FHV-1 causes respiratory or ocular disease or both that may 
range from mild to severe upper respiratory signs and systemic disease with lethargy, inappetence, 
and sneezing accompanied by nasal and ocular discharges. The acute infection may cause severe 
turbinate and nasal mucosal damage (3, 4) that might predispose the cats to lifelong bouts of bacterial 
nasal infection and sinusitis in sites of previous viral damage (1). During the course of an FHV-1 
infection, the virus establishes itself in the trigeminal nerve ganglia (5). In times of stress and/or 
steroid administration, the latent herpesvirus may cause reactivation of respiratory and ocular signs 
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and viral shedding (2). The persistence of the latent virus is usu-
ally lifelong (1, 6).
Treatment and control of FHV-1 infections in multi-cat 
households have been difficult. Adding lysine to the diet was 
beneficial in a research environment (7) but a recent study in a 
shelter environment found that supplementation with lysine may 
worsen the signs of FHV-1 infections (8). The treatment of acute 
infections with systemic interferon and antiviral drugs has been 
recommended in cats with FHV-1 infections. There was no ben-
efit from ocular administration of feline recombinant interferon 
omega or human recombinant interferon alpha-2b on the clinical 
signs or viral shedding on cats with rhinotracheitis (9). Studies 
using famciclovir in a clinical trial and a series of case studies 
showed an antiviral benefit of the drug (10, 11), but it caused 
adverse events in 17% of the cats in the field application (12).
The herpesvirus disease can be controlled via cell-mediated 
immune response (1, 5). Polyprenyl immunostimulant (PI) is a 
veterinary biologic that modulates the immune response (13). 
We tested its ability to modulate and reduce the severity of the 
clinical disease. Our evaluation of clinical outcomes was based 
on the model that uses sign severity scores for nasal and ocular 
discharges on a scale from 0 (no disease) to 2 (severe disease) 
based on the veterinarian standard of practice.
MaTerials anD MeThODs
The studies presented here were carried out in compliance with 
U.S. Code of Federal Regulations (CFR) Title 9, and other laws 
governing research with veterinary biologics and animal studies 
at institutional, local, state, and federal levels. The studies were 
approved by the Institutional Animal Care and Use Committee 
of the University of Tennessee, protocols # 1946-0910 and 1654-
0910. All cats were adopted after the completion of the efficacy 
studies.
safety studies Design
The cats were monitored for the following adverse events defined 
by the Veterinary Dictionary for Drug Regulatory Activities, 
which included death, aggression, hyperactivity, vocalization, 
lymphadenopathy, abdominal pain, diarrhea, gastroenteritis, 
vomiting, anaphylaxis, angioedema, wheals, mouth rash or swell-
ing, stinging or offensive taste, joint pain, muscle pain, lameness, 
ataxia, tremor, not drinking, anorexia, decreased appetite, general 
pain, weakness, depression, fever, lack of efficacy, loss of weight, 
poor feed conversion, tachypnea (other than panting), dyspnea, 
panting, sneezing, nasal discharge, cough, and ocular discharge. 
Each observer was provided the list of reportable events and 
directed to report their occurrence.
acute high-Dose safety study
Five specific pathogen-free (SPF) cats 12–14 weeks of age were 
randomly selected after the efficacy study. The cats were housed 
in the research facility in individual cages and were identified 
by ear tattoos. The cats had no signs of the disease. All cats were 
given 5 mg/kg (10× therapeutic) dose of PI orally and observed 
for 24 h for clinical signs of toxicity. No other interventions were 
provided.
Field safety study
A field safety study was done in 2009 through 2010 in compliance 
with Title 9 of the CFR and approved by State Veterinarians of the 
10 states where the study was conducted. The sample comprised 
390 domestic cats of any breed, sex, and age. All cats without clini-
cal disease established by their veterinarians and whose owners 
volunteered for the study were eligible. The study was overseen by 
veterinarians working with these cats.
Participating veterinarians were provided with PI, consent 
and observation forms. They were instructed on the product 
administration, record keeping, and reporting adverse events 
during and post-trials. The forms also included a preprinted list of 
reportable adverse events, and the owners and veterinarians were 
instructed to report those. PI was administered 0.5 mg/kg orally 
twice daily for at least 14 days by owners at their homes. The doses 
were calculated by the veterinarians. The times of medicating and 
observations were recorded daily by the owners and presented to 
veterinarians who validated the observations and returned the 
forms for evaluation.
efficacy study Design
Participants and Eligibility Criteria
The studies were performed by the team at the University of 
Tennessee, College of Veterinary Medicine (UTCVM), the loca-
tion closest to the manufacturer; the study Director Alfred M. 
Legendre and support staff have previously worked on PI evalua-
tion. The study was done at the Veterinary Research Facility (VRF) 
at UTCVM in Knoxville, TN, USA. This is an air-conditioned 
indoor facility designed for small animal research and having 
appropriate facilities to prevent transmission of pathogens and 
provide isolation of study cohorts in closed rooms.
Specific pathogen-free cats were purchased for this study from 
Liberty Research Inc., Waverley, NY, USA, in 2007 (20 cats) and 
in 2013 (20 cats). All cats were tested for the lack of disease by the 
seller, and each one had a unique alphanumeric identifier (UID) 
tattooed inside the ears. Cats of any sex of 11–13 weeks of age 
with no clinical disease and having no prior exposure to the virus 
were considered eligible for inclusion. Case definitions are listed 
in Table 1.
interventions
All interventions were recorded on the daily Observation Forms 
for individual cats and on standardized intervention logs. During 
the interventions, the cats were housed in the same room in 
individual steel cases to which they were assigned at the intake.
Treatments were administered to individual cats by the uni-
versity technicians. The volume of the treatment was calculated as 
0.25 mL/kg of cat weight, and an appropriate volume was drawn 
from masked vials labeled with cats’ UIDs. Cats in the PI group 
received 0.5 mg/kg (0.25 mL/kg) of PI orally twice daily on days 0 
through 14 post-challenge. The other group received an identical 
volume of placebo (0.25% aqueous n-butanol). The first dose was 
administered within hours after the challenge.
During the study, nasal and/or ocular discharges were cleaned 
at least once a day as needed. Subcutaneous fluids were adminis-
tered as needed in case of severe dehydration.
Table 1 | case definitions used for the outcomes on the study.
sign or test case definition clinical 
score 
or units
Ocular 
discharge
None 0
Moderate (clear, serous) 1
Severe (mucopurulent with crust formation) 2
Nasal 
discharge
None 0
Moderate (clear, serous) 1
Severe (mucopurulent with crust formation) 2
Nasal 
obstruction
None 0
Moderate (some noisy nasal breathing) 1
Severe (complete nasal obstruction) 2
Salivation None 0
Excessive salivation with visible saliva drooling from 
the mouth
1
Fever Rectal temperature °F
>103.5
>104
Weight 
change
Ratio of weight between days 0 and 14 day post-
challenge (nominator) to weight at day 0 (denominator)
%
Anorexia 
(inappetence)
None (all wet food eaten up overnight) –
Any amount of wet food portion remained not eaten 
overnight
+
Dehydration None 0
Moderate by skin test (skin tenting evaluation—skin 
that is pulled up remains in place greater than 1 s and 
less than 2 s)
1
Severe, requiring fluid therapy, skin remains in place 
longer than 2 s
2
Death or 
euthanasia
Reportable, necropsy required Report
Feline 
herpesvirus 
type 1 (FHV-1) 
presence*
None –
Cytopathic effect observed in the Crandell-Rees feline 
kidney cell culture
+
FHV-1 
antibody titer
None 0
Titer reportable as minimal dilution upon direct titration 
of the sample
Dilution
3
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Blood and oropharyngeal swabs were sampled for laboratory 
testing. The vials were coded with cats’ alphanumeric UIDs. A 
total of 3 mL of blood from the jugular vein of each cat was drawn 
before and after the challenge for measurement of FHV-1 anti-
body titers. Blood serum was separated and immediately shipped 
on ice to Washington State University for serology testing. 
Oropharyngeal swabs were taken before and after the challenge 
to identify the presence of virus. Immediately after sampling, 
oropharyngeal swabs were immersed into 2  mL of Dulbecco’s 
Modified Eagle Medium (DMEM) with 2% fetal bovine serum 
(FBS) and transported to the laboratory within the university 
campus. On day 0, all cats received a total of 1 mL of a 106 TCID50/
mL dose of FHV-1 by administering 1/3 mL in each nostril and 
1/3 mL into the posterior oropharynx.
challenge
Viral Strain and Laboratory Procedures
All virology procedures were done at the Veterinary School 
Diagnostic Laboratory of the University of Tennessee (Knoxville, 
TN, USA), a certified laboratory. The FVR (FHV-1) strain SGE 
was obtained from the United States Department of Agriculture 
(USDA), Ames, IA, USA. The virus used in the challenge was 
grown and titrated by adding 15 μL aliquots of serial dilutions 
to Crandell-Rees feline kidney (CRFK) cell culture in 96-well 
culture plates with DMEM with 2% FBS. The virus titer was 
considered as the highest dilution of the culture that showed 
cytopathic effect (CPE). The challenge was adjusted to 106 of 50% 
tissue culture infectious dose endpoint (TCID50) with minimal 
essential medium.
Each one of seven 25 cm2 flasks with CRFK cell culture was 
supplemented with 5  mL trypsin solution and incubated for 
5–10  min at room temperature. The content was sterily trans-
ferred into 15 mL test tubes, and the cells were pelleted at 1,200 g 
for 2 min. The pellet was resuspended in 3 mL DMEM with 2% 
FBS, and equally split into three 25 cm2 flasks. Previously placed 
oropharyngeal swabs were removed from test tubes, and the 
content was mixed by vortexing, 1.5 mL was removed, syringe-
filtered through 0.2 μm filter and added to the flasks with CRFK 
and incubated for 1  hour at room temperature. Then, 7  mL of 
DMEM with 2% FBS was added, and the flasks were transferred to 
the 37°C CO2 incubator. The flasks were inspected daily for 8 days, 
and results were recorded as CPE-positive (+) or negative (−).
Serology was done by a feline herpesvirus neutralization 
test at Washington Animal Disease Diagnostic Lab, SOP: 
205.7.2010.08.07 (Washington State University, Pullman, WA, 
USA).
Objectives
The objectives of this study were as follows: (1) to evaluate the 
safety of PI in clinically healthy cats of different signalments in 
a field study and (2) to evaluate the efficacy of the product in 
a randomized, blinded, placebo-controlled study with SPF cats 
experimentally challenged with FHV-1.
Outcomes
Case definitions for all outcomes are listed in Table 1. The pri-
mary outcome was severity of the FRV disease measured based 
on standards of practice. Nasal discharge was considered as a 
measure of respiratory disease, and ocular discharge was used as 
a measure of ocular disease. The disease caused by FHV-1 may 
manifest as ocular or respiratory, or both, therefore, the scores for 
nasal and ocular discharges were combined in the case definition.
Secondary outcomes included fever defined as elevated 
rectal temperature over 103.5°F and over 104°F, average rectal 
temperature, weight change between the beginning and the end 
of the trial period, nasal obstruction, dehydration, salivation, and 
FHV-1 antibody titers.
All clinical assessments were performed by Alfred M. Legendre. 
All measurements and interventions followed the same protocol. 
The scales were calibrated daily using weight standards. Pictures 
of all cats were taken during all clinical evaluations. All laboratory 
tests were performed by certified veterinary diagnostic laborato-
ries following standard procedures. After the trials, and before the 
code was broken, the remainder of the formulations in the used 
vials was analyzed for content by thin-layer chromatography, and 
the results were used to confirm the assignments by the pharmacy.
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randomization sequence generation
Randomization occurred at three levels: (1) cats were assigned 
to cages in the random order they were unloaded from the truck 
and processed at the facility; the order of the assignments did not 
follow the order of UIDs listed on packing slip; (2) on 1 day before 
challenge (DBC) of each trial when the pharmacy at the UTCVM 
performed randomization and assigned treatments randomly 
based on the random-number table using UIDs listed on the 
packing slip; (3) during daily clinical observations, the order in 
which Alfred M. Legendre examined cats was randomized using 
www.randomizer.org.
blinding
The manufacturer provided labeled vials with PI and placebo 
(0.25% aqueous n-butanol) to the pharmacy at the UTCVM, 
which is located separately from the VRF. The pharmacy printed 
and affixed its own labels coded with the cats’ alphanumeric UIDs 
onto the vials corresponding to the treatment assignments. The 
pharmacy-labeled vials were given to technicians involved in 
the care of the cats. The firm, the researchers, or the technicians 
involved in the study did not participate in the treatment assign-
ments. Pharmacy personnel did not participate in the care or 
evaluation of the cats and were blinded as to the cats’ assignments 
to cages.
During the study, the researchers and support personnel 
handling the cats and the laboratory samples used alphanu-
meric IDs corresponding to individual ear tattoos as identi-
fiers. As an additional blinding measure to prevent pattern 
formation by Alfred M. Legendre, we applied randomization 
of the sequence of physical examinations of the cats using 
www.randomizer.org. Pharmacy personnel disclosed the key 
to the code to the investigators and support personnel after 
the end of the study.
statistical analysis
Skewness and kurtosis statistics were used to test the assumption 
of normality for all modulation scores. A skewness or kurtosis 
statistic above an absolute value of 2.0 assumed a non-normal 
distribution. Levene’s Test of Equality of Variances was used to 
assess homogeneity of variance between the independent groups. 
If both statistical assumptions were met, then an independent 
samples t-test was used to compare control participants to treat-
ment participants on continuous outcomes like modulation score, 
weight, and temperature. Means and SDs with 95% confidence 
intervals were reported for continuous outcomes. Chi-square 
tests were used to test associations between the treatment groups 
and categorical variables including gender, anorexia, mortality, 
and FHV-1 presence. Frequencies and percentages were reported 
for categorical outcomes.
The baseline clinical characteristics of the cats from the 
second trial were compared to those in the first trial using infer-
ential statistics to confirm that the test subjects were virtually 
identical. These characteristics included weight, age, and gender. 
Independent samples t-tests were used for weight and age, while 
Chi-square was used for the gender comparison. Statistical sig-
nificance was assumed at an alpha value of 0.05 and all analyses 
were conducted using SPSS Version 22 (IBM Corp., Armonk, 
NY, USA).
In our evaluation of the severity of the disease, which is the 
primary outcome, we used a composite score for two outcomes: 
nasal and ocular discharge. The severity of nasal and ocular 
discharges was used to denote modulation of disease states for 
each day of observation; the scores of 0 (no disease present), 1 
(moderate disease), and 2 (severe disease) were added together 
to yield a composite score. Using this scoring methodology, the 
maximum total score for any given day of observation was 4 
(severe for both ocular and nasal signs) and the minimum total 
score per day was 0 (no nasal or ocular discharge). With a total 
of 15 days of observation in this study, the highest score possible 
was 60 (the denominator). These modulation scores were added 
together for each day of observation (the numerator) and divided 
by 60 to yield the overall modulation score for each cat.
We compared extent of the severity of the disease in individual 
kittens between the PI and placebo groups. In that analysis, total 
scores per each kitten over the study period were calculated 
intragroup, and the distributions were compared between the PI 
and placebo groups using unpaired, two-tailed Student’s t-test.
Duration of the disease (persistence of the signs) was calcu-
lated as the number of days when at least one sign of the disease 
was present in a cat; the duration data were compared between 
the groups using unpaired, two-tailed Student’s t-test.
Chi-square tests were used to evaluate the significance of 
the intervention between the treatment groups with regard to 
dehydration where the total count of tests for dehydration over 
the observation period served as the denominator (300 for each 
group, the count of daily measurements in 20 cats over 15 days) 
and the count of recorded events (frequency) of dehydration 
served as a numerator for each treatment group. The same 
approach was used to evaluate fever ≥ 103.5°F and fever ≥ 104°F 
and salivation.
The unpaired, two-tailed Student’s t-test was used to evaluate 
the effect of treatment on FHV-1 antibody titers at the end of the 
trial [14 day post-challenge (DPC)], change in the body weight 
between days 0 and 14 DPC and average body temperatures.
resUlTs
Pi is safe
Polyprenyl immunostimulant was evaluated in an acute high-
dose safety study on 26 September 2007 and a field safety study 
in 2009–2010 and found to be safe. In the acute high-dose safety 
study, the five SPF cats given a single 5  mg/kg oral dose (10× 
therapeutic dose) of PI had no adverse effects noted over the next 
24 hours.
In the field safety study, observation forms reporting admin-
istration schedules and observations were collected from owners 
and veterinarians of 390 cats in 10 states and analyzed. The sample 
comprised 202 females and 188 males between 2 days and 16 years 
of age. The ages of cats on the study were: from 2 days to 4 weeks 
(53 cats, 13.6%), over 4 weeks to 8 weeks (75 cats, 19.2%), over 
8 weeks to 6 months (121 cats, 31.0%), over 6 months to 3 years 
(96 cats, 24.6%), and over 3 years to 16 years (45 cats, 11.5%).
Table 2 | reasons of death or euthanasia of the cats during or after the 
field safety study.
state Type of 
operation
number of dead 
or euthanized 
cats
reason
TX No-kill rescue 18 Sixteen deaths of sick, abandoned 
kittens (2 days to 4 weeks of age), 
without queens, due to upper 
respiratory tract disease and 
malnourishment; one death due to 
an undiagnosed upper respiratory 
problem and one death in a cat 
infected with feline leukemia virus
AZ Breeder 2 Effusive feline infectious peritonitis 
(FIP)
NE Multiple-cat 
household
1 Non-effusive FIP
OH No-kill rescue 3 Effusive FIP
Total 24
FigUre 1 | clinical study design and flowchart. DBC, days before 
challenge; DPC, days post-challenge; BL, bleeding; OPS, oropharyngeal 
swabs.
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Three hundred fifty-nine (92%) of the cats received the PI for 
14 or more days with the remaining 32 (8%) treated for less than 
14 days. The reasons for protocol deviation included: death due 
to preexisting grave conditions (24, see Table 2), exacerbation of 
chronic colitis (1), owner’s discretionary decision to terminate 
their involvement in the study (2), cats were adopted (2), cat 
disliked the taste (1), cat developed diarrhea (1), caretaker had 
an insufficient supply of PI (1).
Adverse events not attributed to PI included a total of 24 
deaths because of preexisting grave conditions. Twenty-three cats 
died before the end of the treatment; one cat with advanced feline 
infectious peritonitis (FIP) died immediately after the end of the 
treatment. Table  2 summarizes the findings by the attending 
veterinarians. Five cats had effusive FIP when started on the PI, 
and one cat had advanced non-effusive FIP. Other adverse events 
during testing not attributed to PI toxicity were non-fatal. One 
owner noted that nine 7- to 9-week-old kittens from the same 
owner who had been previously weaned returned to nursing the 
queen after starting on the PI. One cat with chronic colitis before 
starting on the PI had a recurrence of colitis after starting PI. 
None of these events were considered by the USDA as an indica-
tion of toxicity from the PI.
Four adverse events were attributed to the PI. One cat had 
diarrhea, which started soon after the first dose of PI was given, 
and the PI was discontinued following the incident. Three cats 
exhibited a strong dislike for the taste or smell of PI. No other 
events were reported by the owners and veterinarians that were 
attributed to the PI.
efficacy study
Study Flow
Specific pathogen-free cats identified with alphanumeric ear tat-
toos were delivered in individual crates to the UTCVM Research 
Facility. Upon unloading from the delivery truck, cats were 
randomly assigned to individual stainless steel cages in the same 
room and tagged with collars bearing tattoo ID and cage number. 
Each cat was given dry cat food and water ad lib and wet food 
once daily.
The study flow is shown in Figure  1. All interventions, 
deviations, and observations were recorded daily on standard-
ized forms, which were collected, reviewed, and signed by Alfred 
M. Legendre or technicians daily. Ear UIDs were validated every 
time each cat was handled for interventions or examinations. 
Laboratory test reports were filed together with the observation 
forms. Scales used in cat weighing were calibrated daily using 
weight standards. The cats were acclimated for at least 7  days 
before the experimental challenge (DBC; conditioning period). 
Cats were allowed to play together in the same room every day for 
2–3 h during the conditioning period as well as during a 14-DPC 
period.
All cats were evaluated for the lack of clinical disease at 7 DBC 
(2007) or 8 DBC (2013), 5 DBC, and day 0. A total of 3 mL of 
blood from the jugular vein of each cat was drawn on 7 (2007) 
or 8 (2013) DBC, 0 (2013), 3 DPC (2013), 7 DPC, and on 14 
DPC for measurement of FHV-1 antibody titers. Oropharyngeal 
swabs were taken on 7 DBC (2007) or 8 DBC (2013), 0 (2007), 
and 7 DPC.
The cats were challenged on day 0 and received a total of 1 mL 
of a 106 TCID50/mL dose of FHV-1 by administering 1/3 mL in 
each nostril and 1/3  mL into the posterior oropharynx. Cats 
in the PI group received 0.5 mg/kg (0.25 mL/kg) of PI orally 
twice daily on days 0 through 14 post-challenge. The other 
group received an identical volume of placebo (0.25% aqueous 
n-butanol). The first dose was administered within hours after 
the challenge. The cats were clinically evaluated daily after the 
Table 4 | Outcome statistics summary.
Outcome Units Treatment group Placebo group p-Value
Severity of rhinotracheitis Modulation scores 0.21 ± 0.12 0.30 ± 0.15 0.05*
Duration of rhinotracheitis (persistence of the disease) Days 7.65 ± 2.39 9.35 ± 3.03 0.06
Individual disease severity Severity scores 12.65 ± 6.88 17.70 ± 8.77 0.05*
Weight change
Day 0 g 1,380.30 ± 131.59 1,351.25 ± 170.63 0.41
14 day post-challenge (DPC) 1,421.8 ± 205.41 1,431.45 ± 259.14
Average body temperature °F 101.95 ± 1.02 101.99 ± 1.13 0.55
Fever ≥39.7°C (103.5°F) Frequency 25 32 0.9
Fever ≥40°C (104.0°F) Frequency 11 21 0.07
Feline herpesvirus type 1 antibody titer on 14 DPC Titer 0.12 ± 0.07 0.12 ± 0.08 0.73
Outcome definitions, unit descriptions, and CI 95% intervals are in the text.
*Statistical significance.
Table 3 | baseline characteristics of cat cohorts in the polyprenyl immunostimulant efficacy trials.
2007 2013
Variable Treatment Placebo Treatment Placebo
n 10 10 10 10
Weight at day 0, g (M ± SD) 1,400.7 ± 145.9 1,424.6 ± 196.7 1,359.9 ± 119.8 1,277.9 ± 104.0
Age at day 0, days (M ± SD) 90.4 ± 2.5 90.4 ± 2.5 78.3 ± 3.5 79.9 ± 5.1
Sex, n
Male 5 5 5 7
Female 5 5 5 3
6
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experimental FHV-1 challenge until 14 DPC. The same clini-
cian (Alfred M. Legendre) did the physical examinations in a 
random sequence. The exams included measurement of weight 
and rectal temperature, scoring the severity of nasal discharge 
and nasal obstruction, and scoring the severity of ocular dis-
ease by ocular discharge. Dehydration and salivation were also 
scored.
During the study, nasal and/or ocular discharges were cleaned 
at least once a day. If case of severe dehydration (Score 2), subcu-
taneous fluids were administered.
All cats were seronegative prior to the experimental challenge 
and seropositive after the challenge.
Dates Defining Periods of the study
The study was conducted from 4 September 2007 (day 0, inocula-
tion) through 25 September 2007 (last day of daily observations) 
and from 15 January 2013 (Day 0) through 30 January 2013 (last 
day of daily observations). After the end of daily observations, the 
cats remained at the research facility and were observed periodi-
cally until all cats cleared signs, were vaccinated, neutered, and 
adopted. Twenty cats were used in each trial for a total of 40 cats. 
Every attempt was made in the 2013 study to replicate exactly 
the 2007 study. The same study protocol was used by the same 
research team at the University of Tennessee.
baseline
Both parts of the study involved cats of the same age from the 
same source: domestic shorthair SPF. Baseline characteristics of 
treatment cohorts are presented in Table 3. All cats (20/20 in 2007 
and 20/20 in 2013) were 11–13 weeks of age and clinically healthy 
at the three prechallenge evaluations. Prechallenge tests for virus 
isolation from oropharyngeal swabs and serology indicated the 
lack of the virus and FHV-1 and antibodies in all 40 cats. All 40/40 
cats met the inclusion criteria.
numbers analyzed
All cats completed the assigned treatments; 20/40 cats received 
placebo and the other 20/40 were treated with PI as intended. All 
cats enrolled into the study survived, and all data were collected.
Outcomes
After the inoculation, all 40 cats developed nasal discharge. Ocular 
discharge was observed in 13/20 cats in the PI group and 15/20 
cats in the placebo group. One cat in the placebo group had a mild 
nasal discharge throughout the whole study, whereas one cat in 
the PI group was severely affected. The daily clinical scores for 
nasal and ocular discharges were added and compared between 
groups. Table  4 shows summary statistics for the outcomes in 
both groups.
There was no significant difference in antibody titers, expressed 
as dilutions, between the treatment group (M = 0.12, SD = 0.07) 
and the placebo group (M = 0.12, SD = 0.08) measured on 14 
DPC, p = 0.73. No virus was identified on day 8 pre-challenge 
from oropharyngeal swabs from cats, whereas FHV-1 was iso-
lated from all oropharyngeal swabs taken on 7 DPC confirming 
that all cats in the study were infected with the FHV-1.
The assumptions of normality and homogeneity of vari-
ance were met for the between-subjects comparison of control 
FigUre 3 | Total severity scores in individual cats were significantly 
lower in the cats treated with polyprenyl immunostimulant (n = 20) 
compared to the cats treated with placebo (n = 20), p = 0.05, 
unpaired, two-tailed student’s t-test. Each point represents total severity 
scores of an individual cat during 0–14 DPC.
FigUre 2 | severity scores for nasal and ocular discharge in the 
polyprenyl immunostimulant (Pi)-treated (n = 20) and placebo (n = 20) 
groups. Control participants had significantly higher modulation scores over 
the course of the experiment in comparison to treatment participants, 
p = 0.05 (independent samples t-test).
FigUre 4 | Duration of the disease (persistence of ocular and/or 
nasal discharge) in individual cats in the Pi-treated (n = 20) and 
placebo (n = 20) groups was not significant, p = 0.06, unpaired, 
two-tailed student’s t-test. Each point represents the number of days 
when an individual cat presented with either or both signs during 0–14 DPC.
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experiment in comparison to control participants (M =  0.30, 
SD = 0.15), p = 0.05, 95% confidence interval [95% CI] of dif-
ference 0.00003–0.1683, η2 = 0.10, power = 0.52. Total severity 
scores for individual cats were significantly lower in the PI-treated 
group compared to placebo (p  =  0.05, 95% CI of difference 
0.0021–10.10, η2 = 0.10, power = 0.51; Figure 3). No significant 
difference was observed between the groups in the duration of the 
persistence of the signs (p = 0.06; Figure 4).
A total of 73% (29/40) of the cats had fever at least once 
during the 14  days after the virus challenge. Fever equal to or 
greater than 39.7°C (103.5°F) was recorded 25/300 times in the 
PI in experimental and 32/300 in placebo groups [odds ratio 
(OR) = 0.76, 95% CI = 0.44–1.32]. The difference was not sta-
tistically significant, p = 0.34 (chi-square test). Fever of ≥40.0°C 
(104.0°F) was observed in 11/300 in the PI group and in 21/300 in 
the placebo group (OR = 0.53, 95% CI 0.25–1.11). The difference 
between frequencies of observations was not statistically signifi-
cant, p = 0.07 (chi-square test). The difference between average 
body temperatures also lacked significance, p = 0.55, η2 = 0.02, 
power = 0.29 (unpaired, two-sided Student’s t-test).
Over the 14 days after challenge, the mean and SD of the cat’s 
weight went from 1380.30 ± 131.59 g to 1421.80 ± 205.41 g in 
the PI group and 1351.30 ± 170.63 g to 1431.45 ± 259.14 g in the 
placebo group. The differences were not statistically significant, 
participants to treatment participants; Figure 2 shows the dynam-
ics of the clinical scores for the disease severity over the duration 
of the study. Treatment participants had significantly higher 
modulation scores (M = 0.21, SD = 0.12) over the course of the 
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p = 0.41, η2 = 0.03, power = 0.28 (unpaired, two-sided Student’s 
t-test).
Dehydration of various degrees was observed in seven cats in 
the placebo and eight cats in the treatment group; however, the 
frequencies did not differ significantly. Seven cats in the PI group 
required fluid therapy for a total of nine applications and five 
cats in the placebo group required a total of eight applications of 
fluid therapy for dehydration. The difference was not statistically 
significant. Severity scores of salivation did not differ significantly 
between the groups.
Our intent to analyze modulation of nasal obstruction was 
unsuccessful because the sign was transient and changed after 
sneezing or activity. Therefore, we are not reporting any statistical 
findings on this outcome.
No cat in the study developed mouth ulcerations. No animals 
died or were euthanized during the trial. After the trial, all ani-
mals were either adopted to individuals (35/40) or remained at 
UTCVM colony (5/40).
adverse events
No adverse events from the use of PI were noted throughout the 
study.
DiscUssiOn
Feline herpesvirus-1 infection is a common cause of respiratory 
disease in cats worldwide. Control of the herpesvirus disease 
requires support of the immune response where severity of signs 
and time to resolution depend on the equilibrium between viral 
evasion of the immune system and effective immune protection 
(14). We hypothesized that control of signs of feline rhinotrachei-
tis can be achieved through modulation of the immune response 
and therefore PI, an immunomodulator, should decrease the 
severity of the clinical disease.
Feline herpesvirus type 1 can produce severe illness especially 
in young cats and presents a higher threat to younger cats and 
kittens; therefore, in our safety study, we specifically focused on 
the safety in younger kittens, and 128/390 cats (32.8%) on our 
study were under 8  weeks of age. Adverse reactions in 4/390 
cats (1%) included an immediate onset of diarrhea (1) and an 
active dislike of the taste or smell of the PI (3). Whereas the 
intent was to assess safety in normal cats/kittens, a number 
of the participants tried PI in their sick cats. The 24 lethal 
events reported as adverse on the evaluation forms were due 
to preexisting diseases and not considered PI-related (Table 2), 
including FIP (6/24), feline leukemia virus infection (1/24), an 
undiagnosed, preexisting severe respiratory problem (1/24), 
and malnourishment in neonatal, orphaned kittens (16/24). 
PI caused no adverse events at the 10× therapeutic dose in the 
acute toxicity study.
The experimental study was designed as randomized, double-
blinded, placebo-controlled and involved SPF cats challenged 
with a standard strain used in the development and evaluation 
of rhinotracheitis vaccines by other groups (5, 15). The challenge 
followed by an immediate treatment was similar to the clinical 
trials with famciclovir (10).
The trial was intended as an efficacy study for licensing of PI 
by the USDA and was conducted under the legal requirements 
for clinical trials. Those requirements [reviewed by Kleist (16)] 
directed the selection of the outcomes and the scoring system. 
In line with the regulations, our definition of clinical disease 
included two disease-defining: upper respiratory disease scored 
by the severity of nasal discharge and ocular disease scored by 
the severity of ocular discharge. The scoring of each sign was 
limited to 0–1–2 (no sign–moderate–severe) to allow unequivo-
cal and reproducible evaluation based on the obvious differences 
between serous and mucopurulent discharges.
Individual variability in the severity of the signs within 
the groups was the reason we did not see a significant differ-
ence between the scores in the groups in our first trial in 2007 
(p = 0.09); there was insufficient statistical power of the sample 
(too few cats). Twenty cats were considered the maximum 
number of cats that could be reasonably studied at one time with 
the available resources, e.g., room size, team size, and evalua-
tion requirements. US regulations allow combining data from 
separate clinical trials provided that the trials are similar. Our 
two challenge experiments were virtually identical with respect 
to protocol, therapeutic dose, number of cats in the groups, age 
of cats, challenge regimen, and research team. The cats came 
from the same source, and there was no statistically significant 
difference between signalments in the cat samples in both stud-
ies. Furthermore, the course of the disease in the groups in both 
studies was identical. The difference in the scores between the 
groups was significant (p = 0.05) after the data from the two tri-
als were combined. USDA accepted the data from the combined 
trials and licensed PI.
The signs of upper respiratory and ocular disease have been 
extensively used as markers of the efficacy of vaccines designed 
to protect against rhinotracheitis (1–4, 15, 17, 18). We used the 
composite score for the disease comprising two primary, measur-
able outcomes. The composite score did not include secondary 
outcomes such as nasal obstruction or non-specific signs such 
as fever, anorexia, dehydration, and salivation. The effect of PI 
on secondary outcomes (i.e., non-specific signs) was analyzed 
separately, for each sign, as required by the regulations (16), and 
no significant difference in the severity of secondary outcomes 
was found between the treatment and placebo groups.
In our studies, we used a scale similar to vaccine and drug 
efficacy studies. Serous nasal and ocular discharges were con-
sidered as less severe (score of 1) than mucopurulent discharges 
[score of 2; Ref. (12, 15, 18, 19)]. The absence of a sign received a 
score of 0. While nasal obstruction and sneezing are commonly 
mentioned as signs of the disease, we excluded those from our 
analysis because those signs are highly variable over short periods 
of time, making it difficult to grade them consistently.
All cats in both groups developed signs of FHV-1 infection 
at some time in the study, and the progress of the disease was 
as described by others (15, 18, 19). We restricted our analysis 
to days 0–14 DPC, which is the well-recognized duration of the 
virus-induced phase of the disease (1). Even in SPF cats of the 
same age and infected with the same strain of the FHV-1 virus, 
severity of the clinical signs varied a great deal within both groups 
in our study, in line with those previously reported in natural (1) 
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and experimental (17) infections. One cat in the placebo group 
developed only minimal signs, two kittens in the placebo, and two 
kittens in the PI group developed an extremely severe disease.
The overall analysis identified a statistically significant decrease 
in severity of the nasal and ocular signs of rhinotracheitis in the 
group treated with PI compared to placebo-treated cats in spite 
of considerable individual variations in both groups (p = 0.05). 
PI also reduced summary scores for individual kittens in the 
treated group compared to placebo (p =  0.05). No significant 
difference was observed between the groups in the duration of 
the persistence of the signs (p = 0.06), although the result may be 
due to the insufficient sample size.
Reducing the severity of clinical signs is beneficial in improv-
ing the quality of life of the cats while they are recovering from 
FHV-1 infection and may be associated with a reduction of the 
epithelial necrosis and the damage to the turbinates that occurs 
with herpesvirus, thereby reducing the long-term sequelae such 
as chronic nasal infections and sinusitis. FHV-1 replicates in the 
nasal turbinates (1, 3) and can cause permanent damage. Damaged 
turbinates provide an area for secondary bacterial infections that 
can cause permanent signs of rhinitis.
Treatment of rhinotracheitis has been difficult and has con-
sisted mainly of supportive care such as maintaining hydration 
and electrolyte balance, cleaning nasal discharges, broad spec-
trum antibiotics to prevent secondary infection, and encouraging 
eating (3). Recent studies done in a shelter environment noted 
worsening of the respiratory signs in cats supplemented with 
lysine (8). Earlier studies with valacyclovir found it to be too toxic 
for use in cats with FHV-1 infections (20).
Recently, a number of groups reported the use of famciclovir, 
an antiviral drug (10). In the comparable model with the experi-
mental infection, Thomassy et al. (11) demonstrated that in the 
experimental infection, famciclovir reduced viral load and sever-
ity of the disease. We cannot make a direct comparison between 
the efficacy of PI and famciclovir because the scoring was done 
in very different ways. The clinical efficacy of famciclovir was 
evaluated by a composite score of five primary and secondary 
outcomes: the sum of interrelated endpoints consisting of upper 
respiratory signs (sneezing and nasal discharge) and interrelated 
ocular signs (conjunctivitis, blepharospasm, and ocular dis-
charge), with more scoring grades, and a potential highest score 
of 24 versus the highest potential score of 4 in our study. While 
the use of composite scores and the increase in the number of 
scoring grades adds power to the sample and requires fewer cats 
and fewer observation points, we chose not to combine primary 
and secondary and interrelated outcomes because this method 
may affect the validity of the conclusions (21). Based on our safety 
studies, PI was much safer than famciclovir, which caused adverse 
reactions in 17% of the treated cats (12).
Polyprenyl immunostimulant reduces clinical severity of the 
disease probably through immunity upregulation but has no 
effect on viral or antibody titers. Because of the dosage frequency 
and its application as an oral liquid, PI is easier to administer than 
pills. Simultaneous treatment with antiviral and immunomodu-
latory compounds has been successfully used in human medicine 
for HIV, hepatitis C, and other diseases and may be an option 
in the management of feline rhinotracheitis. PI and famciclovir 
represent two separate classes of treatments and both appear to 
reduce the severity of FHV-1 infections. No studies have been 
done to see if the famciclovir and PI effects can complement each 
other.
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